Posted by Michael Wonder on 09 Feb 2022
NICE terminates yet another appraisal of daratumumab
9 December 2022 - NICE has attempted to appraise daratumumab six times; three have had to be terminated.
NICE is unable to make a recommendation on the use of daratumumab in combination with bortezomib, melphalan and prednisone for patients with untreated multiple myeloma because Janssen did not provide an evidence submission.
As usual, NICE will review this decision if Janssen decides to make a submission.
